Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
Retrieved on:
Friday, August 27, 2021
European Society of Cardiology, INSERM, Population, Blood pressure, Myocardial infarction, Genomics, Scientific Centre of Monaco, Angiotensin, BID, GLOBE, Phase, Biomarker, Medical research, Inserm, Magnetic resonance, National Research Corporation, Paris Descartes University, Hyperkalemia, Heart, IIB, Pathology, Kidney failure, Hypertension, Safety, QUORUM, ESC, Patient, ACE, CEO, Euronext Growth, MRI, Angioedema, III, Brain, CNRS, Heart failure, Medical device, Pharmaceutical industry, Phosphorus
The QUORUM study demonstrates the efficacy and good safety profile of firibastat.
Key Points:
- The QUORUM study demonstrates the efficacy and good safety profile of firibastat.
- In severe patients with an ejection fraction less than 50%, firibastat appears to be more effective than ramipril.
- For this reason, QUORUMs phase IIb results pave the way for a phase III clinical study in severe patients whose protocol will be finalized with a selected partner pharmaceutical company.
- Highlights from the phase IIb QUORUM study are included below:
295 patients were enrolled in the study within 24 hours of a first myocardial infarction.